Abstract. Chemotherapy is one of the main treatment options for cancer, but the effectiveness of chemotherapeutic drugs is severely limited due to their systemic toxicity. Therefore, the need for a more targeted approach in tumor treatment is obvious. A tumor-activated agent would decrease systemic toxicity as well as increase the efficacy of the treatment. It has previously been shown that the latency of pro-TGF-ß is conferred by dimerization of two latency-associated peptides (LAP) that form a protective shield, which is cleaved off upon activation by matrix metalloproteinases (MMPs). It has also been shown that the fusion of this LAP peptide with other cytokines can confer their latency. In the present study, a recombinant adenovirus with a fusion gene encoding a tumor-activated pro-cytolytic peptide was made in which the LAP domain of TGF-ß was fused with melittin, a potent cytolytic toxin, with an MMP2 cleavage site in between the two. In vitro studies show that the melittin-MMP2-LAP recombinant adenovirus can be activated by MMP2 which leads to the release of free melittin to lyse the target cells. In vivo studies show approximately a 70% decrease in B16 tumor volume in melittin-MMP2-LAP recombinant adenovirustreated mice as compared to control mice. No significant systemic toxicity was observed in the treated mice.
Introduction
Despite the progress in developing new strategies for tumor treatments (1-7), chemotherapy remains the main option for systemic treatment in the majority of cancer patients. The effectiveness of chemotherapeutic agents is, however, severely limited by their systemic toxicity, due to the fact that the majority of clinically used anti-tumor drugs are cytotoxins. These cytotoxins mainly target dividing cancer cells as well as dividing non-cancerous cells. Therefore, it is obvious that a more tumor-selective agent would decrease the systemic toxicity and improve the overall efficacy. One of the most direct approaches to this objective is to design prodrugs that will be specifically activated and released when they reach the vicinity of a tumor cell or mass (8) (9) (10) . Transforming growth factor ß (TGF-ß) is unique among cytokines in that it is secreted as a latent cytokine with an N-terminal domaintermed latency-associated peptide (LAP) (11) . LAP is cleaved extracellularly and then forms dimers through disulfide binding. The LAP serves as a shell to protect the C-terminal portion of the cytokine from functioning as well as prevent degradation. Upon activation, the active TGF-ß is released from this shell by proteolytic cleavage of the LAP domain (12) . Taking advantage of this natural LAP protective shell, a hybrid IFN-ß with a LAP domain and an MMP cleavage site has been successfully engineered to target inflammation sites (13) . This latent IFN-ß will only be activated by MMP cleavage. This result indicates that LAP could be used to engineer other latent peptides with varied biological functions (14) .
Membrane-disrupting lytic peptides have been studied intensively for experimental tumor treatment due to their potent, mechanical cell membrane-disrupting capability (15) . Different types of cytolytic toxins, such as anthrax toxin, aerolysin, two-chain ·-hemolysin, and hecate have been used in fusion proteins or conjugates to either directly target the tumor cell surface through ligands and receptors, or be activated through tumor-specific proteases, such as urokinase, PSA, cathepsin B and MMPs (16) (17) (18) (19) . In a previous study, we have shown that an MMP2 cleavable melittin, the poreforming toxin from honey bee, conjugated with avidin can specifically target tumor cells in vitro and in vivo (20) . It has also been shown that recombinant adenovirus encoding a melittin gene controlled by an AFP promoter is effective against hepatocellular carcinoma in vivo (21) . In the present study, an MMP2 cleavable fusion gene between LAP and melittin was constructed. When delivered through recombinant adenovirus, this latent fusion protein can specifically target tumor cells in vitro and in vivo. were used to determine the cell viability of the samples by measuring the luminescence (RLU) of each sample. The gain was set at 150 to read all the samples. The percent decrease was calculated as follows: (RLU; MMP2 treatment -RLU; no MMP2 treatment)/RLU; no MMP2 treatment) x100.
Materials and methods

Melittin
Recombinant melittin-MMP2-LAP adenovirus production.
To produce the recombinant adenovirus, melittin-MMP2-LAP was first cloned into the pDC312 shuttle vector (Microbix; Toronto, Canada). Both the shuttle vector and melittin-MMP2-LAP/pIRES (described above) were cut with NheI and EcoR1 and ligated to produce melittin-MMP2-LAP/pDC312. Secondly, Ad293 cells obtained from Microbix were co-transfected with melittin-MMP2-LAP/pDC312 and pBHGlox(‰)E1,3 Cre (Microbix) plasmid DNA by use of calcium phosphate (Profection mammalian transfection system; Promega). Transfected cells were maintained in normal Ad293 media (DMEM + 10% FBS) and approximately 1 week after transfection, CPE (cytopathic effect) was visible and then cells were collected and lysed via freeze-thaw cycles. Lysate was tested for the presence of mellitin-MMP2-LAP via Western analysis using human LAP antiserum as described above. Recombinant adenovirus was amplified according to standard protocols (BD Adeno-X Expression System1), purified via ViraBind Adenovirus purification kit (Cell Biolabs; San Diego, CA), and tittered by use of QuickTiter Adenovirus Titer Immunoassay Kit (Cell Biolabs). The units for the viral titer were IFU/ml. Recombinant virus was then concentrated using 100K MWCO centrifugal filter units (Sartorius Stedim; Edgewood, NY).
Recombinant melittin-LAP (MMP2 del.) adenovirus production.
In order to make an MMP2 cleavage control adenovirus, another recombinant adenovirus was produced in which the MMP2 cleavage site was deleted; melittin-LAP (MMP2 del.). The MMP2 cleavage site was deleted by using inverse PCR. Melittin-MMP2-LAP/pDC312 was used as the template and the following primers synthesized by Operon Biotechnologies Inc. (Huntsville, AL) were used in the PCR reaction; leftmuta (GCCGCCCTGCTGTCTCTTGC) and rightmuta (GGCGGCCTGAGCACCTGTAAGA). Both primers were phosphorylated at their 5 prime ends and SDS-PAGE purified. The protocol from the Phusion Site-Directed Mutagenesis Kit obtained from NEB was followed for the Inverse PCR reaction. After Inverse PCR the product was gel-purified using the QIAquick gel purification kit from Qiagen. The PCR product was then circularized with Quick T4 DNA ligase (NEB) in a 5 min reaction and following ligation was transformed into TOP 10 cells (Invitrogen). Several of the transformants were analyzed and it was confirmed by sequencing that the MMP2 cleavage site had been deleted. This recombinant adenovirus was then amplified, purified and tittered as described in the above section titled 'melittin-MMP2-LAP recombinant adenovirus production'.
In vitro cytotoxicity assay using melittin-MMP2-LAP recombinant adenovirus. In order to perform in vitro cytotoxicity assays with the recombinant adenovirus, DU-145 cells were plated at a cell density of 5,000 cells/well in an opaque-walled 96-well plate. The volume of cells in each well was 100 μl. After 24 h, DU-145 cells were infected with either AD5.CMV LacZ control adenovirus (Quantum Biotechnologies, Montreal, Canada), melittin-LAP (MMP2 del.) recombinant adenovirus, or melittin-MMP2-LAP recombinant adenovirus at a multiplicity of infection (MOI; infectious units/cell) of 0, 100, 500 and 1000. Cells were treated with virus for approximately 72 h and the CellTiter-Glo luminescent cell viability assay (Promega) was then done according to the vendor's protocol. Luminescence values for each sample were measured by use of the Lumistar (BMG Labtech) and the gain was set at 150. Decrease was calculated using the following equation: (RLU; melittin recombinant adenovirus or RLU; deleted cleavage site -RLU; Ad5.CMV LacZ adenovirus)/RLU; Ad5.CMV LacZ adenovirus) x100.
In vivo tumor killing. In order to determine the effectiveness of the melittin-MMP2-LAP adenovirus in vivo, 10 C57bl6 female mice (Jackson Lab, Bar Harbor, ME) approximately 8 weeks of age were inoculated with 0.5x10 6 B16 melanoma cells s.c. Prior to mouse inoculation, B16 tumor cells were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum and 50 μg/ml gentamicin (Gibco). The mice used for this study were housed according to the rules of the Institutional Animal Care and Use Committee. Eight days following B16 tumor inoculation 5/10 mouse tumors were injected with 100 μl (2.5x10 8 IFU) melittin-MMP2-LAP adenovirus and 5/10 mice were injected with an equal amount of AD5. CMV LacZ control virus (Quantum Biotechnologies). Mice were injected twice a week for a total of 5 injections. Prior to each injection mice were weighed and tumor volume was measured (w 2 xL/2). At the end of the study, mice were sacrificed, tumors were removed and weighed.
Statistical analysis. All statistical analyses were performed using GraphPad Prism software. The unpaired t-test was used to calculate P-values. Data were considered significant at P<0.05.
Results
Construction of melittin-MMP2-LAP fusion gene.
The melittin-MMP2-LAP fusion gene was synthesized by GenScript Corp and a schematic of the melittin-MMP2-LAP fusion gene is shown in Fig. 1 . The fusion gene is approximately 942 base pairs in size and consists of 4 main segments. The first segment encodes amino acids 1-29 of the original TGF-ß secretion signal peptide, followed by the complete melittin sequence, and a flexible MMP2 cleavage site (GGGSPQGIAGQGGG). The final segment of the fusion gene encodes amino acids 30-273 of the latency-associated peptide (LAP) domain of TGF-ß.
Expression of melittin-MMP2-LAP fusion protein in CHO/
dhFr-cells. CHO/dhFr-cells were chosen for melittin-MMP2-LAP fusion protein production. CHO/dhFr-cells were transfected with melittin-MMP2-LAP/pIRES/dhFr plasmid DNA and were selected by G418 addition (final concentration 1 mg/ml) as well as HT depletion. Expression of the melittin-MMP2-LAP fusion protein is shown in Fig. 2 . The predicted molecular weight of the melittin-MMP2-LAP fusion protein is approximately 35 kDa. A protein approximately this size is shown by Western analysis with hLAP antibody in the melittin-MMP2-LAP transfected cells, but not in the untransfected CHO cells.
Amplification of melittin-MMP2-LAP fusion gene via MTX.
In the CHO/dhFr-cell system for protein expression, MTX can be used for gene amplification and therefore increased melittin-MMP2-LAP protein production in CHO cells. Fig. 3 shows that the production of the melittin-MMP2-LAP fusion protein was amplified by use of MTX. Normally the melittin-MMP2-LAP CHO cell line is cultured in the presence of 100 nM MTX. By gradually increasing the concentration of MTX in the cells from 100 to 1000 nM MTX, melittin-MMP2-LAP fusion protein expression could be increased as shown by the Western analysis in Fig. 3 . Protein expression is increased in samples incubated with up to 500 nM MTX. At a concentration higher than 500 nM MTX, for example 1000 nM, protein production is decreased. Fig. 4 represents data obtained from an in vitro cell viability assay. This assay was performed to determine whether or not the protein secreted from the transfected cells was functional. The protein is considered functional if in its secreted form it can be cleaved by MMP2. Once the fusion protein is cleaved, the melittin portion of the peptide will interact with the MMP2 secreting cancer cells and kill them. To activate the fusion protein, both CHO and melittin-MMP2-LAP-transfected CHO cells (50nM MTX) were treated with active MMP2 for 72 h. After MMP2 treatment, cell viability assays were done to determine the percent decreases in luminescent signal (RLU values) in MMP2-treated-transfected and non-transfected cells as compared to cells with no MMP2 treatment. The luminescent signal (RLU) correlates with the viability of the cells and therefore, as RLU values increase, cell viability also increases. It can be seen from Fig. 4 that the melittin-MMP2-LAP-transfected CHO cells show a greater % decrease in RLU as compared to untransfected CHO cells. These data demonstrate that most likely the fusion protein secreted from the transfected cells is functional since it is cleaved by MMP2. Cleaved peptide will attack the cells, decrease cell viability, and therefore result in a lower luminescent signal as compared to untransfected CHO cells.
Cell death is increased in melittin-MMP2-LAP-transfected CHO cells treated with MMP2 as compared to untransfected CHO cells.
Production of recombinant Melittin-MMP2-LAP adenovirus.
To produce the recombinant adenovirus, Ad293 cells were co-transfected with melittin-MMP2-LAP/pDC312 shuttle vector plasmid DNA and pBHGlox(‰)E1,3 Cre plasmid DNA for recombinant adenovirus production as described by the manufacturer's protocol (Microbix). Recombinant protein production was demonstrated by Western analysis using hLAP antiserum as shown in different MOI (multiplicity of infection) of either melittin-MMP2-LAP, melittin-LAP (MMP2 del.), or the Ad5.CMV LacZ recombinant adenovirus. The MMP2 deletion adenovirus was used as a control for the functionality of the MMP2 cleavage site and the Ad5.CMV LacZ recombinant adenovirus was used as the control virus. After 72 h of infection, Fig. 6 shows that the level of cell viability is decreased in the melittin-MMP2-LAP virus-infected cells thus resulting in a greater % decrease in RLU values as compared to the melittin-LAP-(MMP2 del.) infected cells. The RLU values obtained at a specific MOI for both the melittin-MMP2-LAP and melittin-LAP (MMP2 del.) adenoviruses are directly compared to the RLU value for Ad5.CMV LacZ-infected cells. At a MOI of 100, 500 and 1000, there are significant decreases (P<0.5) in cell viability in the melittin-MMP2-LAP-infected cells as compared to the cleavage site deleted form of the adenovirus. The calculation for % decrease is described in the 'Materials and methods' section.
Melittin-MMP2-LAP recombinant adenovirus reduces tumor size in vivo.
In order to determine the effects of the melittin-MMP2-LAP adenovirus in vivo, intratumor injections using the recombinant adenovirus were done in mice bearing B16 tumors. Ad5.CMV LacZ was used for the control intratumor injections. Fig. 7A shows that at the start of intratumor injections, the average tumor volume in both groups was about the same. After 5 injections (2.5 week period), there is a significant decrease (70% decrease) in tumor volume in melittin-MMP2-LAP virus-treated mice as compared to Ad5. CMV LacZ-treated mice ( Fig. 7B; P=0.003, n=5) . At the end of the study, mice were sacrificed, tumors were removed from mice, and weighed. The melittin-MMP2-LAP-treated mice showed approximately a 70% reduction in tumor mass as compared to control mice as demonstrated in Fig. 8 (P=0.02,  n=5 ).
Discussion
Various strategies have been studied to design tumor-targeted lytic peptides (15) . These peptides are tumor selective, fast acting, and less likely to develop resistance. In the present study, the very potent mammalian cell lytic melittin was converted into a latent peptide by fusing it with the LAP domain of TGF-ß. The latent melittin can be reactivated with active MMP2 since an MMP2 cleavage site was engineered between the melittin sequence and the LAP domain. The data presented in this paper demonstrate the following: CHO cells transfected with melittin-MMP2-LAP expression vector were lysed when active MMP2 was added into the culture; recombinant adenovirus encoding the melittin-MMP2-LAP fusion gene lysed DU-145 human prostate tumor cells in vitro, which has been shown to secret active MMP2 (20) ; and direct intratumoral injection of this recombinant adenovirus significantly reduced the tumor burden.
Previous studies have shown that the fusion of IFN with the LAP domain on its N-terminal can form a better shell as it is found in the native TGF-ß (15) . In the present study, fusion of melittin at its C-terminal resulted in a latent lytic peptide, which will regain its cytolytic activity once cleaved by MMP2. When melittin was fused at its N-terminal with LAP, the fusion protein had no lytic activity, but melittin also lost its lytic activity after it was released from the fusion protein by MMP2 (data not shown). This is probably caused by the extra amino acid residues left from the MMP2 cleavage site since the hydrophobic N-terminal residues are critical for the formation of the helical structure as well as the activity of melittin (17) .
Lytic peptides are known for their fast-acting and shortsystemic half-life (15) . It has been shown in previous work with cytokines that IFN fusion with LAP has a longer halflife (13) . By fusion with the LAP domain, melittin could have a longer half-life, especially if delivered via recombinant adenovirus, but still behave as a fast-acting compound once released by MMP2 cleavage. This could be beneficial in terms of keeping a constant pressure on the tumor but avoiding the risk of building up drug resistance like regular chemotherapeutics.
TGF-ß has been shown to be overexpressed in human tumors (22) (23) (24) (25) . The recombinant proregion of TGF-ß exhibited antagonist activity against active TGF-ß in a transgenic mouse model (26) . The LAP domain cleaved from the fusion protein could be another factor generated in the present study to have anti-tumor activity. This could be answered in the future with a LAP domain only virus as the control.
MMP-2 and other MMPs play a very important role in normal tissue-remodeling events such as embryonic development, angiogenesis, ovulation, mammary gland involution and wound healing. MMP2 is also involved in osteoblastic bone formation and/or inhibits osteoclastic bone resorption (27) . This will certainly limit the use of the current approach under those physiological conditions. Although the in vivo data from the current study suggest that the experimental mice tolerated well the treatments, any prediction on the possible side-effects of the present study has to be cautious mainly because the recombinant adenovirus was injected directly into the tumor mass and the lytic peptide has a very fast kinetics of action. These two factors can certainly prevent meaningful amounts of the fusion peptide produced inside the tumor from leaking out and activating somewhere else.
